See original article in english Antitrust in Life Sciences #1 Life science mergers I: New US and EU rules & recent cases

Webinar

Antitrust in Life Sciences #1 Life science mergers I : New US and EU rules & recent cases

1er webinaire de la conférence « Antitrust in Life Sciences 2021 » organisé par Concurrences, en partenariat avec Gibson Dunn et Herbert Smith Freehills, avec Paul Csiszar (Director - Basic Industries, Manufacturing and Agriculture, DG COMP), Kyriakos Fountoukakos (Associé, Herbert Smith Freehills), Stacy E. Frazier (Executive Counsel - Competition Law and Policy, General Electric), Josh Kaul (Procureur général, Wisconsin Department of Justice), Stephen Weissman (Associé, Gibson Dunn) et Robert Willig (Professeur, Princeton University).

- Interview de Paul Csiszár, par Kyriakos Fountoukakos : Accessible pour tous (voir ci-dessus)

- Présentations PPT : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Vidéo : Accessible aux abonnés Concurrences+ (voir ci-dessous)

- Audio : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Synthèse : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Retranscription : Accessible aux abonnés Concurrences+ (voir ci-dessus)

- Documentation liée à l’événement (Cliquez sur Voir plus ci-dessous)

- Articles Concurrences (Cliquez sur Voir plus ci-dessous)

Consultez la section "Prochaines Conferences" pour vous inscrire aux futurs webinaires.


SYNTHÈSE

Robert Willig indicated that new laws have been proposed to renew antitrust in the US and to make it stricter. However, they would likely make antitrust more arbitrary rather than more strictly rigorous and rational. For instance, one of the main projects is the Competition and Antitrust Law Enforcement Reform Act (CALERA) proposed by Senator Amy Klobuchar. It creates a presumption of illegality for all mergers that would significantly raise concentration or for which the parties would reach more than 50 percent market share in any relevant market post-combination. If such were the case, the burden would be on the parties to demonstrate that the merger would not diminish competition in the market. But how can a life sciences firm carry that burden by demonstrating entry or rival expandability or the wrong choice of “any” relevant market, without access to rivals’ confidential information on R&D capabilities, roadmaps and capacity that is crucial for assessing dynamic competition ?

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

Speakers

  • DG COMP (Brussels)
  • General Electric (Washington)
  • Herbert Smith Freehills (Brussels)
  • Compass Lexecon (Washington)
  • Wisconsin Department of Justice
  • Gibson Dunn (Washington)

Testimonial